Remdesivir, an experimental antiviral drug from Gilead Sciences, has shown promise based on early results in people with severe COVID-19, the disease caused by the new coronavirus.
But experts caution that data from randomized studies are still needed to determine if the medication is safe and effective. "While it is reassuring to hear reports of cohorts with good outcomes, it is impossible to interpret the impact that remdesivir is having on a group that has been treated with this drug in the